GPR3 (G-Protein Coupled Receptor 3) is a constitutively active Gs-coupled GPCR that is widely expressed in the brain, particularly in the hippocampus, cortex, and basal ganglia. Originally identified as an orphan receptor, GPR3 has emerged as an important therapeutic target for neurodegenerative diseases due to its roles in amyloid processing, neuroinflammation, and neuronal survival. [1]
GPR3 is encoded by the GPR3 gene and is classified as a Class A GPCR. Key features include:
The receptor is located on neuronal membranes throughout the CNS and can also be found on glial cells. Its constitutive activity makes it a unique pharmacological target. [2]
GPR3 modulators work through multiple pathways relevant to neurodegeneration:
Amyloid Processing: GPR3 activation promotes non-amyloidogenic APP processing through alpha-secretase, reducing amyloid-beta production. This is mediated through cAMP/PKA signaling. [2:1]
Neuroprotection: Constitutive GPR3 activity promotes neuronal survival through CREB-mediated gene expression.
Anti-inflammatory Effects: GPR3 modulation can reduce microglial activation and neuroinflammation. [3]
Synaptic Function: GPR3 signaling supports synaptic plasticity and cognitive function.
GPR3 is a high-priority target for AD due to:
GPR3 modulators may provide benefit in PD through:
GPR3 remains an emerging target with limited clinical development. Key compounds include:
| Compound | Development Stage | Key Properties |
|---|---|---|
| GPR3 antagonists | Preclinical | Reduce amyloid in models |
| GPR3 inverse agonists | Preclinical | Modulate constitutive activity |
| Allosteric modulators | Discovery | Bias signaling |
| Property | Value |
|---|---|
| Target | GPR3 (G-Protein Coupled Receptor 3) |
| Drug Class | GPCR modulator (orthosteric or allosteric) |
| Signaling | Gs-coupled, beta-arrestin |
| **BBB Penetration | Required for CNS indications |
Tang J, et al. GPR3: a potential therapeutic target for Alzheimer's disease. J Alzheimers Dis. 2021. ↩︎
Huang SM, et al. GPR3 functions in amyloid-beta production and mediates beta-arrestin signaling. Cell. 2010. ↩︎ ↩︎
Ye R, et al. GPR3 modulates neuroinflammation and protects dopaminergic neurons. Neuropharmacology. 2022. ↩︎